Details
Aim : A retrospective analysis in SIBDC patients investigated efficacy and safety in IBD patients treated with vedolizumab as first-line therapy. Results of the study have been presented at DDW 2019.
Contact: frank.seibold@magendarmsuisse.ch
Aim : A retrospective analysis in SIBDC patients investigated efficacy and safety in IBD patients treated with vedolizumab as first-line therapy. Results of the study have been presented at DDW 2019.
Contact: frank.seibold@magendarmsuisse.ch